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Abstract 
 
Chondroitin sulphate proteoglycans (CSPGs) are the main active component of 
perineuronal nets (PNNs). Digestion of the glycosaminoglycan chains of CSPGs with 
chondroitinase ABC or transgenic attenuation of PNNs leads to prolongation of object 
recognition memory and activation of various forms of plasticity in the adult CNS. The 
inhibitory properties of the CSPGs depend on the pattern of sulphation of their 
glycosaminoglycans, with chondroitin 4-sulphate (C4S) being the most inhibitory form. 
In this study we tested a number of candidates for functional blocking of C4S, leading 
to selection of an antibody, Cat316, which specifically recognises C4S and blocks its 
inhibitory effects on axon growth. It also partly blocks binding of semaphorin 3A to 
PNNs and attenuates PNN formation. We asked whether injection of Cat316 into the 
perirhinal cortex would have the same effects on memory as chondroitinase ABC 
treatment. We found that masking C4S with the Cat316 antibody extended long-term 
object recognition memory in normal wild type mice to 24 h, similarly to chondroitinase 
or transgenic PNN attenuation. We then tested Cat316 for restoration of memory in a 
neurodegeneration model. Mice expressing tau with the P301S mutation showed 
profound loss of object recognition memory at 4 months of age. Injection of Cat316 
into the perirhinal cortex normalised object recognition at 3 h in P301S mice. These 
data indicate that Cat316 binding to C4S in the extracellular matrix can restore 
plasticity and memory in the same way as chondroitinase ABC digestion. Our results 
suggest that antibodies to C4S could be a useful therapeutic to restore memory 
function in neurodegenerative disorders.  
 
Key words: Perineuronal nets, CSPGs, Object recognition memory, Plasticity, 
$O]KHLPHU¶V disease 
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1. Introduction 
 
Memory loss is a largely unmet medical challenge. Halting brain degeneration would 
be the most effective form of treatment, but it has yet to be achieved. An alternative is 
to enable the brain to function despite the degenerative damage. Plasticity enables the 
brain to bypass damage, but it is limited in adults by inhibitory proteoglycans in the 
brain extracellular matrix situated in perineuronal nets (PNNs), which surround key 
regulatory neurons. 
PNNs are dense pericellular extracellular matrix (ECM) structures with a structure 
similar to cartilage that develop at the time of closure of critical periods for plasticity. 
PNNs are a highly organised complex, mainly composed of hyaluronan, chondroitin 
sulphate proteoglycans (CSPGs), link proteins, and tenascin-R. The form of PNN most 
studied are those surrounding parvalbumin-positive (PV) interneurons recognised by 
the lectin WFA, although other forms of PNN exist around pyramidal and other neurons 
(Matthews et al. 2002). In the cortex PNNs surround PV interneurons which are known 
to influence plasticity and excitability, and PNNs are involved in the termination of 
plasticity at the end of critical periods (Fawcett, 2015,Pizzorusso, et al., 
2002,Sugiyama, et al., 2009). PNNs are also involved in memory. Depletion of 
chondroitin sulfate (CS) with the chondroitin sulphate digesting enzyme, 
chondroitinase ABC (ChABC) prolonged object recognition memory in normal mice 
(Romberg, et al., 2013), restored lost memory in a neurodegeneration model in 
tauopathy mice and Abeta transgenic mice (Vegh, et al., 2014,Yang, et al., 2015), and 
affected fear memory extinction (Gogolla, et al., 2009), demonstrating that CSPGs are 
the key molecules in regulating this form of memory, and that the CS 
glycosaminoglycan (GAG) chains digested by ChABC are their effectors. Animals 
deficient in the PNN component Crlt1 link protein have very attenuated PNNs and 
show the same changes in memory and plasticity as animals treated with ChABC 
despite having unaltered CSPGs in the CNS, demonstrating that it is CSPGs in PNNs 
that are controllers of plasticity and memory (Carulli et al., 2010; Romberg et al., 2013). 
However, in order to reactivate plasticity, ChABC has to be injected directly into the 
brain parenchyma where it digests a region of up to 1 mm across, and the effect lasts 
for around three weeks. ChABC is therefore not a practicable treatment for memory 
restoration in neurodegenerative diseases. This study investigates antibody treatment 
as an alternative. 
 
CSPGs and PNNs are implicated in neurodegenerative conditions in various ways.  
CSPGs are abundant in DP\ORLG DQG QHXURILEULOODU\ WDQJOHV LQ $O]KHLPHU¶V GLVHDVH 
(AD) (reviewed in (DeWitt, et al., 1993,Kwok, et al., 2011) and differentially sulphated 
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CS such as chondroitin 4-sulphate (C4S), chondroitin 6-sulphate (C6S) and 
unsulphated chondroitin were detected (DeWitt, et al., 1993). A  reduction of PNNs in  
brains affected by AD was shown by staining with lectin WFA (Baig, et al., 
2005,Kobayashi, et al., 1989), although many markers were not affected in AD patients 
and animal models of AD (Morawski, et al., 2012c,Morawski, et al., 2010b).  PV 
interneurons are largely unaffected by neurofibrillary tangles (Baig, et al., 
2005,Bruckner, et al., 1999,Hartig, et al., 2001,Morawski, et al., 2010a,Morawski, et 
al., 2012b).This suggests that PNNs may be protective, and there is evidence for 
regulation of ion homeostasis (Suttkus, et al., 2014b), and neuroprotection against 
oxidative stress (Cabungcal, et al., 2013,Suttkus, et al., 2014a). Treatment with 
chondroitinase does not affect hyperphosporylated or filamentous tau (Yang, et al., 
2015), but an effect on Abeta quantity has been reported (Howell, et al., 2015). 
 
The functional effect and binding properties of CSPGs are heavily dependent on the 
patterns of sulphation of their GAG chains (Lin, et al., 2011,Malavaki, et al., 
2008,Miyata and Kitagawa, 2015). The sugars in the GAG chain can be sulphated in 
the 4, 6, 2+6 and 4+6 positions on the CSs (C4S, C6S, C2,6S and C4,6S, also known 
as CS-A, CS-C, CS-D, CS-E)  respectively, and different patterns of sulphation give 
motifs that can provide specific binding sites (Mikami and Kitagawa, 2013,Xu and 
Esko, 2014,Yabuno, et al., 2015). C4S is inhibitory to neurite growth while C6S is more 
permissive to neurite growth and to plasticity (Lin, et al., 2011,Miyata, et al., 
2012,Wang, et al., 2008). Thus mice with a knockout of chondroitin 6-sulfotransferase 
1 (C6ST1) showed worse regeneration and less plasticity than wildtypes (Lin et al., 
2011) while C6ST1 overexpressing mice demonstrated enhanced plasticity into 
adulthood (Miyata et al., 2012). During embryonic development C6S predominates, 
but at the end of the critical period in the PNN fraction only 4.9% of CS-GAG is 6-
sulphated while 80.6 % is the inhibitory 4-sulphated form (Carulli, et al., 2010,Deepa, 
et al., 2006). We have recently demonstrated that this trend continues into aging when 
memory deficits start to appear. Chondroitin 6-sulfate reduced almost to zero in aged 
rats (12- and 18-months old) when compared to young animals (Foscarin et al., 2017). 
Moreover, the sulphation pattern of PNN CS-GAGs (which make up 2% of total brain 
CS-GAG) is different from that of the general brain matrix, giving the PNN specific 
binding properties (Deepa, et al., 2006). Thus semaphorin 3A (Sema3A) and OTX2 
bind specifically to PNNs but not to the general matrix (Beurdeley, et al., 2012,Dick, et 
al., 2013,Miyata, et al., 2012,Vo, et al., 2013), where they are positioned to affect 
synapse dynamics and PV cell maturation. Both these molecules bind most strongly 
to 4,6 disulphated CS-GAG. The major CSPG core protein of PNNs is aggrecan, which 
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is necessary for PNN formation (Carulli, et al., 2016,Dick, et al., 2013,Giamanco, et 
al., 2010,Morawski, et al., 2012a) and contains specific glycan modifications in its 
linkage region (Yabuno, et al., 2015).The CS-GAGs carried by aggrecan are probably 
the key component of PNNs that regulate memory and plasticity, because animals 
lacking aggrecan in the CNS show the same memory prolongation phenotype as 
animals with attenuated PNNs due to Crtl1 knockout or ChABC treatment (unpublished 
observations) (Romberg, et al., 2013). Our hypothesis therefore was that masking C4S 
on aggrecan would make PNNs less inhibitory, and would therefore have a similar 
effect to ChABC in restoration of memory to brains damaged by neurodegeneration, 
or in prolonging memory in normal animals. 
 
Seeking potential treatments for memory restoration, we have tested an inhibitory 
proteoglycan neutralising antibody. In this manuscript, we have identified Cat316 as a 
C4S binding antibody that can modulate the inhibitory properties of the glycan, reduce 
Sema3A binding, prolong object recognition memory in normal animals and restore 
lost memory in tauopathy animals. 
 
2. Materials and methods 
 
2.1. Screening of PNN blocking antibodies using PNN-HEK cells 
PNN-HEK cells (~12,000 cells) were plated on poly-L-lysine coated coverslips for 2 h 
and cultured in low-serum medium (0.5 % fetal bovine serum in DMEM) in the 
presence of 5 % CO2. Detached cells were then removed with a rinse in fresh warm 
medium. Potential PNN blocking antibodies (Cat316 is from Millipore; HAPLN1 is from 
R&D; 6B4 and 7B7 are from CosmoBio) were diluted into 5 µg/ml in cultured medium 
before incubation with the PNN-HEK cells for 48 h at 37qC with 5 % CO2. Control 
treatment with ChABC (200 mU/ml for 30 min) was done after plating. Then cells were 
rinsed in warm culture medium, and stained with anti-aggrecan antibody (1:400, rabbit 
polyclonal, Millipore) for 30 min for PNNs. Cells were then fixed with 4 % 
paraformaldehyde (PFA) before incubation with secondary anti-rabbit antibodies. Cells 
were counterstained with Hoechst, coverslipped with anti-fading medium FluoroSave 
(CalBiochem) before visualised using Leica confocal microscope.  
For experiments testing the efficiency of Cat316 in blocking Sema3A from binding to 
the PN-HEK cells, PNN-HEK cells were cultured as above and Sema3A (40ng/ml) was 
added to the culture medium for 2 h at 37qC. The cells were then rinsed with warm 
DMEM twice for 10 minutes each at 37qC before being processed for 
immunocytochemistry of Sema3A using a protocol as above. 
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2.2. Quantification of optical density of aggrecan staining in PNN-HEK cells 
All images were captured with the same settings using a Leica confocal microscope 
[with 1 frame at numerical aperture 1.15, 405 nm laser (12%), 488 nm laser (38%) and 
532 nm laser (38%)]. The red channel corresponding to aggrecan staining of the PNNs 
was converted into black and white images. Optical density of the images was 
measured using ImageJ software (1.49v, National Institutes of Health, USA). The data 
was then normalised first to a negative control (omitting primary antibodies), before 
further normalisation against the positive control (i.e. PBS). For each condition, 5 
random images were taken from each coverslip with 4 coverslips per experiment. Each 
experiment was repeated three times.  
 
2.3. Neurite outgrowth assay 
Dorsal root ganglia (DRGs) were dissected in cold DMEM from adult Sprague-Dawley 
rats (~ 3 months). The DRGs were dissociated in collagenase (0.2 % w/v in Hanks-
DMEM buffer) and trypsin (0.1% w/v in PBS) before being reconstituted in culture 
medium (1x insulin-tryptophan-selenium, 10 ng/ml nerve growth factor in DMEM). The 
neurons were then plated onto laminin (1 µg/ml) or aggrecan-laminLQ  ȝJPO
ȝJPOFRDWHGFRYHUVOLSV7KH'5*QHXURQVZHUHFXOWXUHGIRURUh with or without 
the addition of different PNN blocking antibodies (5 ng/ml) including HAPLN1, Cat316, 
6B4 and 7B7. For the control, the coverslips were treated with ChABC for 30 minutes 
before the plating of the DRGs. The neurons were then fixed using 4% PFA. The 
neurites were stained with anti-beta III tubulin antibody (1:1000, chicken, AbCam) and 
IB4-fluorescein lectin (1:250, Sigma). The longest neurite per neuron was measured 
using ImageJ software (1.49v, National Institutes of Health, USA). Twenty neurons 
were measured per coverslip and 3 coverslips were prepared per condition in each 
experiment. Each experiment has been repeated 4 times. The number of neurons 
bearing neurites (i.e. the neurites were longer than the diameter of the cell bodies) was 
also counted in each coverslip under 20x magnification and 5 random views were 
counted per coverslip. The results were compared to the total number of neurons in 
the same visual field.  
 
2.4. Slot blot assay for antibody specificity 
Commercial CSs were purchased from Sigma Aldrich (for CS-A, -B, -C and aggrecan) 
and Seikagaku (CS-D and -E). Each CS was prepared as 2 and 10 µg/ml in distilled 
water, then transferred to a nylon membrane using a slot blot cassette. The blots were 
blocked with 5 % skimmed milk before incubating with the anti-CS antibodies. After 
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incubation, the blots were rinsed and probed with alkaline phosphatase conjugated 
secondary antibodies (Invitrogen, 1:500). The binding of antibodies was visualised 
using alkaline-phosphatase substrate (NBT/BCIP; Sigma).  
 
2.5. Enzyme linked immunosorbent assay (ELISA)  
The ELISA was modified from Dick et al. 2013. Biotinylated GAGs (0.5 g per well) 
isolated from loose extracellular matrix (B1) or PNN matrix (B4) were immobilized onto 
streptavidin- coated plates of 384 (Pierce/Thermo Scientific). Biotinylation of GAGs 
was performed by EDC and biotin-LC hydrazide conjugation (Pierce/Thermo 
Scientific). After GAGs were immobilized on the plates, the plates were blocked in 1% 
BSA and subjected to the binding of recombinant Sema3A-AP (150 ng/ml). Detection 
of Sema3A-AP was done by direct measurement of absorbance at 405 nm using p-
nitrophenyl phosphate (Sigma). To detect binding of Sema3A-GFP, the wells were 
incubated with 1:2,000 rabbit anti-Sema3A antibody (Abcam), and subsequently with 
1:10,000 AP-conjugated anti-rabbit antibody (Invitrogen). Detection was done by 
measuring the absorbance at 405 nm using p-nitrophenyl phosphate.  
 
2.6. Mice 
The normal wild type (WT) C57BL/6J (Charles river, UK) mice were used for Cat316 
antibody treatment study and subjected to the long-term object recognition (OR) 
memory test with 24 h delay paradigm. Transgenic mice as a dementia model used 
for this manuscript were homozygous Tg P301S tau mice expressing human mutant 
P301S tau under the control of the murine Thy1.2 promoter (Allen, et al., 2002). Age- 
and sex-matched C57BL/6J mice (Charles river, UK) were used as WT controls. Male 
mice were used across the studies. Animals had unrestricted access to food and water, 
and were maintained on a 12 h light/dark cycle (lights off at 7:00 P.M.). All experiments 
were carried out in accordance with the UK Home Office Regulations for the Care and 
Use of Laboratory Animals and the UK Animals (Scientific Procedures) Act 1986.  
 
2.7. Anti-CSPG antibody Cat316 injections 
Anti-CSPG IgM antibody Cat316 (1mg/ml in PBS), or isotype control IgM (1mg/ml, 
Abcam) was stereotaxically injected to six different sites in the perirhinal cortex (PRh; 
SHUKHPLVSKHUHȝOZLWKDVSHHGRIȝOPLQ. Animal surgeries were performed 
under isoflurane anesthesia. Injections were made ZLWKDȝO+DPLOWRQV\ULQJHDQG
a 33 gauge needle at the following sites (in mm from bregma and the surface of skull): 
1. anteriorposterior (AP): -1.8; lateral (L): ± 4.6; ventral (V): -4.4. 2. AP: -2.8; L: ± 4.8; 
V: -4.3. 3. AP: -3.8; L: ± 4.8; V: -3.8.  The needle remained in place at the injection site 
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for 3 min before being slowly withdrawn over 2 min. After two days of first injections, 
additional injections were performed as described above.  
 
2.8. Spontaneous Object Recognition task 
The spontaneous OR task was performed three days after second injections of Cat316 
or isotype control antibody. The protocol was slightly modified from the previously 
published protocol (Yang et al, 2015). All mice were habituated in two consecutive 
daily sessions in the empty Y-maze apparatus for 5 min prior to surgery. After recovery 
from surgery, animals received one day of habituation session for 5 min. Each test 
session consisted of a sample phase and a choice phase. In the sample phase, the 
animal was placed in the start arm and left to explore two identical objects, which were 
placed on the end of two arms for 5 min. The choice phase followed after a delay of 
either 3 h or 24 h, which the animal spent in the home cage.  The choice phase was 
procedurally identical to the sample phase, except that one arm contained a novel 
object, whereas the other arm contained a copy of the repeated object. When the 
animals were assessed, a different object pair was used for each session for a given 
animal, and the order of exposure to object pairs were counterbalanced within and 
across groups. In the experiment using a P301S tauopathy model, a different object 
pair was used for each session for a given animal, and the test sessions were 
separated by a minimum of 48 h. The object exploration time was assessed from video 
recordings of the sample and choice phase. The direct nasal or head contacts only 
were regarded as an exploratory behaviour. A discrimination ratio was calculated by 
dividing the difference in exploration of the novel and familiar objects by the total object 
exploration time. Therefore, the discrimination ratio varies from 0 (equal exploration for 
novel and familiar objects) to 1 (exploration of the novel object only). The test sessions 
were separated by a minimum of 48 h. Group means were compared by ANOVA 
followed by Tukey post hoc test with a significance level of p < 0.05, using GraphPad 
Prism version 5.0. A two-tailed t-test was used for two-group comparisons.  
 
2.9. Immunohistochemistry: DAB staining 
Sample preparations and the general procedures of immunostaining have been 
described previously (Yang et al., 2015). In general, 30 µm free floating sections were 
incubated with 10 % methanol, 3 % H2O2 in PBS for 20 min at room temperature for 
quenching endogenous peroxidase activity. Sections were rinsed three times in 0.2 % 
Triton-X in PBS (PBS-T) and were subsequently blocked with 5 % normal goat serum 
(NGS) or normal horse serum (NHS) in PBS-T for 1 h at room temperature. The 
primary antibodies (NeuN; 1:400, Millipore; AT8; 1:1000, Innogenetics; Cat316; 1:50, 
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Millipore; WFA; 1:100, Sigma-Aldrich) were incubated over night at 4 °C  following 
rinsing tissues for 5 min three times in PBS-T (0.2 % Triton-X in PBS). For Sema3A 
staining, as adapted from Vo et al, 2013, tissue sections were pre-incubated with 0.1 
U/ml of ChABC (Seikagaku) in ChABC buffer (0.1 M Tris-HCl, 0.03 M sodium acetate, 
pH 8.0) for 2 h at 37 °C  prior to quenching. Then Sema3A antibody (1:50; Santa Cruz 
Biotechnology) was incubated overnight at RT. Following 3 washes in PBS-T they 
were incubated for 2 h at RT with the appropriate biotinylated secondary antibody 
(Vector Laboratories) diluted 1:500 in PBS-T. For detecting the Cat316 antibody 
injection site, the biotinylated secondary antibody (biotinylated goat anti-mouse IgM, 
1:500, Vector Laboratories) was incubated over night at 4 °C . Subsequently, sections 
were incubated with an avidin-biotin system (Vectastain; Vector Laboratories) for 1 h 
at RT and washed with PBS-T. The immunostaining was visualized with 
diaminobenzidine with 3 % H2O2 (DAB kit; Vector Laboratories) for 1-5 min at RT. For 
Sema3A staining the immunolabelling was performed with diaminobenzidine with 0.3 
% H2O2 for 10-20 min at RT. The sections were mounted on gelatin-coated slides and 
air-dried. Following dehydrating tissue sections in ascending concentration of alcohols, 
they are cleared in xylene and coverslipped with DPX. The tissue sections were 
examined using a light microscope and photographed using a digital camera (Leica 
DM6000 Microsystems). 
For quantification of WFA and Sema3A immunoreactivity, the images were captured 
under 20x object magnification using Leica DM6000 Microsystems. Four to six images 
per animal were randomly captured in the injection area of Cat316 or isotype control 
IgM (n=4 per group). These images, all acquired using the same microscope settings, 
were adjusted by threshold cutoff to 128 in Adobe photoshop CS5 (saved to a black 
and white image) in order to cut out the majority of background staining and black/white 
inverted. Then, ImageJ software (1.49v, National Institutes of Health, USA) was used 
to quantify the number of pixels brighter than the threshold. 
  
3. Results 
The aim of our experiments was to select and evaluate an antibody that can reactivate 
plasticity and restore memory through blocking inhibitory proteoglycans in PNNs. We 
tested several candidates for their ability to block inhibition by PNN proteoglycans, 
from which we selected Cat316. The ability of Cat316 to bind to proteoglycans and 
PNNs and to compete with Sema3A binding to PNNs was then evaluated in more 
detail. We then asked whether Cat316 has the same effects on memory prolongation 
and restoration as chondroitinase digestion. Cat316 was injected into the perirhinal 
10 
 
cortex, and its ability to prolong object recognition memory in normal mice and to 
restore memory in tauopathy mice was measured. 
 
3.1. Selection of a chondroitin-4-sulphate blocking treatment 
Our first task was to find a treatment that could block the inhibitory effects of C4S. In 
order to do this, we measured the binding of candidates to CS-GAGs, assayed for 
blocking inhibition of axon growth by aggrecan and tested for inhibition of PNN 
formation in vitro. Our candidates were antibodies that bind to CS-GAG, the CS-GAG 
binding lectin WFA and an antibody to the PNN component HAPLN1 link protein.  
 
First, we assayed the binding of three antibodies and WFA to different sulphation forms 
of CS-GAG in a slot blot assay. Purified CSs of known sulphation type and aggrecan 
were immobilised on nylon membranes. Incubation with these reagents showed that 
only Cat316 had strong binding to C4S (CS-A) (at both 2 and 10 µg) and aggrecan 
(Fig. 1), but did not bind to C6S (CS-C), C2,6S (CS-D) or C4,6S (CS-E). Two other 
candidate antibodies CS-56 (IgM anti CS-GAG) and AB1031 (polyclonal anti-
aggrecan) did not show preferential binding to C4S (CS-A) (Fig. 1). We also tested the 
CS-GAG-binding lectin WFA, but this bound to aggrecan but not to the isolated CS-
GAGs. The results show that of our candidates only Cat316 bound specifically to C4S.  
 
To test the ability of our candidates to neutralize inhibition of neurite extension in the 
presence of inhibitory CSPGs, we cultured adult DRG neurons on a low concentration 
of laminin in the presence of the inhibitory CSPG aggrecan (Fig. 2). This assay has 
been widely used to assay for the inhibitory effects of CSPGs and CS-GAGs extracted 
from the CNS (Tan, et al., 2012). DRG neurons cultured on mixed laminin/aggrecan 
substrates grew shorter (49.9% reduction) neurites compared to laminin control.  The 
aggrecan inhibition was neutralised when the laminin/aggrecan substrates were pre-
digested with ChABC. Of the various candidates Cat316 antibody and anti-HAPLN1 
also neutralised the inhibition of aggrecan to the same extent as ChABC; the length of 
neurites cultured on laminin/aggrecan/Cat316 was similar to the laminin only condition 
(223.0 r 30.6 µm vs 199.8 r 33.4 µm). The results demonstrate that the only CS-GAG-
binding molecule of our candidates able to block inhibition by aggrecan was Cat316. 
 
We tested the ability of our candidates to inhibit PNN formation. For this we used an 
in vitro model of PNN formation. PNN-HEK cells are surrounded by a PNN-like 
condensed matrix, whose formation is dependent on aggrecan, hyaluronan synthase 
and Crtl1 link protein (Kwok, et al., 2010b). We tested four antibodies, three of them  
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bind to aggrecan (Cat316, 6B4 and 7B7) and one binds to Crtl1 link protein (anti-
HAPLN1) for their ability to block the formation of the PNN-like matrix around PNN-
HEK cells when placed in the growth medium for 48 h (Fig. 3). Aggrecan 
immunostaining and WFA staining were used as markers for PNNs on the cell surface. 
The binding of aggrecan to the PNN structures is partially dependent on its CS-GAG, 
because treatment of cells with ChABC for 30 minutes reduced aggrecan staining on 
the cell surface (Fig. 3B; 61.2% reduction). All the antibodies were able to reduce PNN 
formation, judged by surface aggrecan intensity, on the PNN-HEK cells but to different 
degrees; Anti-HAPLN1 by 28.2%, Cat316 by 55.1%, 6B4 by 17.4% and 7B7 by 17.7% 
(n=4, two-tailed paired t-test, ***p < 0.001). Measurement of the surface intensity of 
WFA showed a reduction when the cells were treated with chondroitinase, anti-
HAPLN1 or Cat316 antibody. These results demonstrate that of the CS-GAG-binding 
antibodies, Cat316 antibody has the most powerful effect on blocking the formation of 
PNNs in PNN-HEK cells.  
 
Based on the above results we selected Cat316 as the most promising treatment for 
blocking the inhibitory effect of C4S on PNN CSPGs, and further characterized its 
effects in two more in vitro assays. 
 
3.2. Cat316 binds to PNN GAGs and inhibits semaphorin 3A binding 
We tested the binding of Cat316 to GAGs purified from diffuse soluble brain ECM (B1) 
and from the PNN-enriched fraction (B4) using a modified glycan ELISA (Dick et al., 
2013). CS-GAGs from brain ECM and PNNs were extracted from adult rat brains, using 
the sequential extraction method in which PNN-GAGs are enriched in the final 6 M 
urea buffer (B4) (Deepa, et al., 2006,Kwok, et al., 2015). These CS-GAGs were 
biotinylated and immobilized in ELISA wells. Cat316 was incubated with the 
immobilised B1-GAGs or B4-GAGs (Fig. 4). The results demonstrated that Cat316 
bound to both B1 and B4 GAGs. This binding was greatly reduced when the GAGs 
were pre-treated with ChABC before the addition of Cat316. This suggests that Cat316 
binds to the ECM and PNN glycans with similar affinity and the binding is mediated 
through the CS-GAGs in the preparation. 
 
A key effector of PNNs is Sema3A, which binds particularly to disulphated C4,6S (de 
Winter, et al., 2016,Dick, et al., 2013). We therefore tested the ability of Cat316 to bind 
to purified brain CS-GAGs from the PNN compartment, and for its ability to block 
Sema3A binding to these CS-GAGs. Both Cat316 (as in Fig. 4) and Sema3A bound 
strongly to these CS-GAGs (Fig. 5A). When Cat316 was added to the PNN-GAGs first, 
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the subsequent binding of Sema3A was approximately halved. We then tested for the 
ability of Cat316 to inhibit binding of Sema3A to an in vitro model of PNNs. PNN-HEK 
cells were cultured to form PNNs, then Sema3A was added for 2 h. As shown in Fig. 
5B, it bound strongly to the extracellular matrix of the cells. Cat316 was then incubated 
with the cells for 2 h before addition of the Sema3A, leading to a reduction (by 38.4%; 
n=3, paired t-test, ***p < 0.001) in binding of Sema3A to the PNN-HEK cell extracellular 
matrix Fig. 5, C and D). These experiments show that Cat316 binds to PNN-like CS-
GAGs and blocks the binding of Sema3A to them.  
 
3.3. Cat316 antibody blocks the inhibition of axon growth on Sema3A and PNN matrix  
We next asked whether Cat316 affects axon growth on PNN-HEK cells to which 
Sema3A is bound. Dissociated DRG neurons were plated on coverslips coated with 
PNN-GAGs (B4-GAGs), then Sema3A for 2 h and cultured in the presence of Cat316 
(Fig. 6). In the presence of Cat316 antibody, the length of neurites was increased on 
PNN-HEK-Sema3A matrix (Fig. 6, B and C). This suggests that Cat316 is efficient in 
blocking Sema3A-induced inhibition on PNN-HEK matrix.  
 
3.4. Cat316 antibody binds to CS-GAGs in perineuronal nets in vivo 
In order to identify the structures that bind Cat316 in mouse brain, sections of rat cortex 
were immunostained with the antibody. The antibody clearly stained PNNs throughout 
the cortex with a low level of diffuse staining to the matrix in the cortex in addition (Fig. 
7). In order to confirm that Cat316 antibody binds to CSPGs in brain sections, the CS-
GAGs were digested by pre-incubating the mouse brain sections for 1 h with ChABC 
at concentrations 0.01 U/ml, 0.1 U/ml, 1 U/ml. After the enzymatic degradation of 
CSPGs the tissues were immunostained with Cat316 (Fig. 7A). Immunoreactivity to 
Cat316 was gradually reduced as concentrations of ChABC increased, indicating that 
the epitope recognized by Cat316 antibody was removed by ChABC treatment and 
was therefore a CS-GAG (Fig. 7A). However, there was still some diffuse staining of 
digested sections, in contrast to WFA staining which was completely removed by 
ChABC treatment (Fig. 7B). We saw a very similar pattern of PNN and diffuse matrix 
staining when the antibody was injected into the perirhinal cortex and detected with 
anti-IgM secondary (Fig. 8A,B). At high magnification the staining revealed a lattice-
like matrix which enwrapped the soma and dendrites in a typical PNN fashion (Fig. 
8B). Fig. 8A shows the spread of the antibody from a single injection, with the planes 
of section at bregma -1.8 mm, -2.8 mm and -3.8mm. The amount of antibody around 
the injection site decreased over time. At 5 days after injection there was strong 
staining with anti-IgM secondary, but by 10 days the staining was very weak. This 
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decline in Cat316 concentration in the brain roughly correlates with the loss of effect 
in the behavioural object recognition memory test (see below). The antibody spread 
for approx. 1mm by diameter from the injection site. 
 
3.5. Sema3A and WFA binding were reduced in Cat316 injected areas 
Having shown above that Cat316 can inhibit the binding of Sema3A to PNNs in an in 
vitro assay, we asked whether we could see a similar inhibition in vivo. Four days after 
Cat316 injection Sema3A levels were measured by immunostaining of wild type mouse 
brain sections (Fig. 9A). Observation of the sections suggested that antibody injection 
reduced strong Sema3A staining of PNNs, but had little effect on weaker and diffuse 
staining. We therefore measured Sema3A staining intensity in the most strongly 
stained regions by thresholding all the images to a level that removed the diffuse stain 
and just left the intensely stained PNNs. We then measured the number of pixels in 
each section that exceeded the threshold. By this analysis, the intensity of Sema3A 
antibody immunostaining was reduced by 33 % (two-tailed paired t-test, *p=0.0157, 
n=4), in the Cat316 injected area compared to the isotype control injection control (Fig. 
9, B and C) We also measured binding of biotin-WFA by measuring staining intensity 
in the perirhinal cortex using the same thresholding method, and this was reduced by 
27% in the injected region after Cat316 treatment to WT control mice compared to 
isotype control injection (two-tailed paired t-test, *p=0.0243, n=4, Fig. 9D and E). 
These results indicate that Cat316 antibody binds competitively to the same binding 
sites as Sema3A and WFA.  
 
3.6. Cat316 antibody enhanced long-term OR memory in wild type mice 
Having demonstrated that Cat316 antibody binds to inhibitory C4S and blocks its 
inhibitory effect on axon growth, and also inhibits PNN formation and the binding of 
Sema3A to PNNs, we asked whether injection of the antibody to the perirhinal cortex 
has the same effect on memory as ChABC. We therefore investigated object 
recognition memory, in which 24 h memory is greatly prolonged after ChABC injection 
or transgenic attenuation of PNNs (Romberg et al 2013, Yang et al 2015). We 
anticipated that blocking inhibitory CSPGs by Cat316 injection to the perirhinal cortex 
would mimic this ChABC-induced memory enhancing effect. The experimental animals 
were habituated in the Y-maze prior to the injections of Cat316 or an isotype control 
antibody. Cat316 antibody was delivered bilaterally to the perirhinal cortex (3 injections 
per hemisphere) twice with two days interval (Fig. 10A). The six injections of Cat316 
were made to bregma AP: -1.8mm, -2.8mm, -3.8mm. WT mice infused with Cat316 or 
control antibody were tested for OR memory retention 5 days after the second 
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injection. Animals treated with Cat316 antibody showed an enhancement of long-term 
(24 h) OR memory compared to controls (Isotype control injected wild type mice) at 5 
days post injection (Isotype control 0.05 ± 0.02, n=9 vs Cat316 0.26 ± 0.05, n=11; two-
tail unpaired t-test, **p=0.0049, Fig. 10B). We then asked whether effect would persist 
as the antibody gradually dispersed from the brain by testing animals at 8 or 11 days 
post injection. At both these time points there was no increase in persistent 24 h 
memory compared to isotype control, indicating that the antibody effect did not persist 
until day 8 after injection (Fig. 10C). Neither Cat316 nor control IgM injections to 
perirhinal cortex affected participation in the test, as measured by the motivation index 
(Fig. 10, B and C). These results show that Cat316 injected into perirhinal cortex has 
the same effect on prolongation of memory as ChABC and that the effect disappears 
as the antibody dissipates.  
 
3.7. OR memory in P301S tau mice rescued by Cat316 antibody treatment 
TgP301S tau mice express a mutant form of human tau which is responsible for 
genetically-determined neurodegeneration in humans (Allen, et al., 2002). Mice 
expressing this gene show progressive tauopathy accompanied by progressive 
memory loss which can be corrected by ChABC treatment (Yang, et al., 2015). This 
mouse line was re-derived into a C57BL/6J background, and OR memory assessed at 
3, 4 and 5 months. TgP301S tau mice showed progressive memory decline with 
profound memory loss at 4M and 5M of age compared to age-matched WT mice whilst 
they have intact memory at 3M of age (Fig. 11A). We selected 4 month-old mice for 
further experiments since they showed consistent impairment in OR memory (WT vs 
P301S, unpaired t-test, ***p=0.0008). This memory loss was seen even at the short 
delay time of 3 h. WT control and Tg P301S tau mice explored the sample objects to 
a similar extent without any side preference, indicating that there was no major 
difference in motivation between groups (Fig. 11A). At this age, approximately 15% 
neuronal cell loss detected by anti-NeuN antibody staining was present in the perirhinal 
cortex compared to the WT control mice (WT 51592 ± 1391 n=7, P301S 43458 ± 1381, 
n=6, unpaired t-test, *p < 0.05).  
Based on our previous work showing restoration of memory in P301S mice after 
ChABC injection into the perirhinal cortex (Yang et al. 2015), and the results in this 
paper showing memory extension in control mice after infusion of Cat316, we next 
tested whether Cat316 infusion in the perirhinal cortex restores the OR memory deficit 
in TgP301S tau mice. Cat316 or isotype control IgM were bilaterally injected at three 
different sites into 4 month-old Tg P301S tau mice. Four and six days after injections 
animals were tested for short-term OR memory, measuring 3 h retention (Fig. 11B). 
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The impaired OR memory shown in 4 month-old P301S mice was normalised to the 
level of control animals after Cat316 antibody treatment while animals treated with 
isotype control IgM showed the same deficit as untreated animals. This was 
comparable to the behavioural restoration as seen in ChABC treated animals (Isotype 
control 0.047 ± 0.09, n=8 vs Cat316 0.28 ± 0.04, n=14, ChABC 0.24 ± 0.05, n=6, One 
way ANOVA, *p=0.042)(Fig. 11C). However, animals injected with either Cat316 or 
ChABC did not show the enhanced 24 h OR memory retention seen in WT animals, 
which was at the same basal level of memory shown in the isotype control group (Fig. 
11C). Following the Cat316 injection the immunostaining profile of tau pathology 
detected by AT8 antibody was not significantly altered (Isotype control 44 ± 17.9 n=6, 
Cat316 41 ± 13.7 n=6)(Fig. 12A,B). Moreover this treatment did not alter the 
progressive neurodegeneration in TgP301S mice, which still showed the same 
reduction in neuronal cell counts compared to WT control mice treated with isotype 
control antibody (WT:Isotype control 1.0 ± 0.03 n=3, P301S:Isotype control 0.84 ± 0.02 
n=5, P301S:Cat316 0.81 ± 0.04 n=6)(Fig. 12C). These data show that Cat316 
injections to perirhinal cortex restore memory in P301S mice to the same extent as 
ChABC treatment, and demonstrate that blocking inhibitory C4S CS-GAGs is sufficient 
to correct the adverse effect on memory of tauopathy-induced neurodegeneration.  
 
4. Discussion 
 
PNNs have been implicated in memory through several types of experiment. In OR 
memory, transgenic attenuation of PNNs or their digestion with ChABC leads to 
memory prolongation (Romberg, et al., 2013). In fear memory ChABC digestion in the 
amygdala restores memory erasure (a form of learning) to the infantile pattern 
(Gogolla, et al., 2009). Memory stimulated by environmental enrichment depends on 
the formation of new inhibitory synapses on PV neurons, and this synapse formation 
is facilitated by ChABC digestion (Donato, et al., 2013).  We have focused on OR 
memory because it depends on a focal brain area ZKLFKLVDIIHFWHGHDUO\LQ$O]KHLPHU¶V
disease, perirhinal cortex, and because of its robust readouts that can be obtained in 
a time scale appropriate for testing treatment effects. Our previous work shows that 
ChABC injected to the perirhinal cortex can prolong OR memory in WT animals or 
restore memory to mice with memory loss caused by pathology due to transgenic 
expression of mutant tau (Romberg et al 2013, Yang et al 2015). ChABC injections 
can also restore memory in an animal model of Abeta pathology (Vegh, et al., 2014) 
All of these experiments depend on the injection of ChABC into the brain, or transgenic 
attenuation of PNNs. In the present work we explored the possibility of using an 
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antibody that recognizes and blocks the most inhibitory form of the CS-GAGs that are 
attached to the CSPGs of PNNs.  
 
Inhibition of regeneration and plasticity by CSPGs is strongly influenced by the pattern 
of sulphation of CS-GAGs in PNNs. Most CS-GAG sugars are 4 or 6 mono-sulphated, 
with 6S being more permissive to axon growth and plasticity, 4S being more inhibitory 
(Lin, et al., 2011,Miyata and Kitagawa, 2015,Miyata, et al., 2012,Wang, et al., 2008). 
In the adult CNS over 90% of CS-GAG is 4-suphated, this proportion increasing as 
plasticity reduces at the end of critical periods (Carulli, et al., 2010,Deepa, et al., 2006). 
The hypothesis behind this study was that blocking the inhibitory effects of 4-sulphated 
CS in PNNs would make the PNNs less inhibitory and consequently reactivate 
neuronal plasticity and affect memory in the same way as ChABC injections.  
 
The first step was to select an appropriate C4S-blocking antibody. We tested a range 
of anti CSPG-antibodies and also the CS-GAG-binding lectin WFA for their ability to 
bind to C4S and to block its inhibitory effects and also to block binding of the PNN 
ligand and effector Sema3A (de Winter, et al., 2016,Dick, et al., 2013,Vo, et al., 2013). 
We also tested for the ability of antibodies to inhibit aggrecan-dependent formation of 
PNN-like structures on PNN-HEK cells (Kwok, et al., 2010a) These PNN-HEK cells 
form PNN-like matrix with a similar chemical composition and hierarchical assembly 
as those found in the brain. From these tests, we selected Cat316 because it binds to 
C4S and aggrecan, inhibits PNN development around PNN-HEK cells, blocks the axon 
growth inhibitory effect of aggrecan, and also partly prevents the binding of Sema3A 
to PNNs. Cat316 was originally identified for its binding to aggrecan in PNNs in the 
visual cortex, the level of staining being affected by dark rearing (Kind, et al., 
2013,Lander, et al., 1997,Matthews, et al., 2002). Surprisingly, WFA, which binds 
specifically to PNNs and is used to stain them for histology, did not bind to any of CS 
isoforms and only bound to aggrecan in a slot blot assay, and did not block aggrecan 
inhibition. This may indicate that WFA lectin binds to PNNs-CS in a conformation-
dependent manner or recognises a specific glycan structure which is yet to be 
identified. WFA certainly recognises CS-GAGs because ChABC treatment, abolishes 
its ability to bind to mouse brain tissue sections. The binding of Cat316 in vivo was 
similar to our in vitro results, with Cat316 binding to PNNs and reducing the association 
of Sema3A with PNNs. Anti-CSPG antibody CS56 binds preferably to 6-sulphated CS, 
which is present in a very minute quantity in PNNs. Anti-aggrecan antibody AB1031 
did not show preferential binding to CS-GAGs. And the other antibodies to aggrecan 
such as 6B4 and 7B7 had no effect in neurite outgrowth assay. Thus, we selected 
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Cat316 to target C4S molecules in extracelluar matrix including PNNs. There are 
unfortunately no other anti-C4S antibodies available, and in particular there is no IgG 
anti-C4S antibody that could be used for systemic treatment. 
 
Having selected Cat316 as the candidate antibody we had to decide how to administer 
it. Because Cat316 is an IgM it presumably has very limited ability to cross the blood-
brain-barrier and also limited ability to diffuse. We therefore decided for this proof of 
concept study to inject the antibody directly by stereotaxic injection into the perirhinal 
cortex.  We infused Cat316 antibody twice to the same injection sites in order to build 
up a sufficient antibody level, and to ensure that Cat316 persists in the cortex during 
the 5 days that it takes to measure OR memory. Staining of Cat316 injections showed 
that the antibody spreads around 1mm from the injection site, and the amount 
remaining at the injection site declined to be barely detectable by 7 - 10 days. First, we 
tested for the ability of Cat316 to prolong memory in control mice. In normal mice OR 
memory does not persist beyond 12 h, but in our previous studies, ChABC treatment 
extended robust memory to 24 h, and memory was still detectable at 48 h (Romberg, 
et al., 2013). We saw a similar effect with Cat316 antibody: treated normal WT animals 
showed strong object memory at 24 h, while in control IgM injected animals objects 
were forgotten by this time. However this treatment effect was of limited duration, 
because when we tested animals at 8 and 11 days after antibody injection they showed 
no prolongation of memory, reflecting the decline in antibody levels at the injection site 
with time.  
 
The next experiment was to see whether we could restore OR memory in a 
neurodegeneration model. For these experiments we used a tauopathy model, in 
which mice express a mutant form of tau protein leading to a progressive loss of 
memory. By 4 months of age these animals can learn and remember objects for a 
short time, but by 3 h the memory has been lost. These animals have a normal number 
and appearance of PNNs (Yang, et al., 2015).  In previous work ChABC injections to 
the perirhinal cortex of tauopathy animals restored the deficit in 3 h memory retention 
to a normal level (Yang, et al., 2015). We saw the same effect after Cat316 infusion in 
a P301S tauopathy model. Memory was restored to the same pattern as WT animals. 
As with ChABC, Cat316 in P301S animals did not cause the prolongation of memory 
to 24 hours and beyond that is seen when WT animals are treated. These results 
indicate that blocking inhibitory C4S CS-GAGs can restore memory function in adult 
animals with a neurodegenerative condition. Neutralizing CSPG by antibody in the 
human tauopathy mice P301S did not alter disease progression. At the time of testing 
18 
 
both treated and untreated animals showed 15% neuronal loss, and the same extent 
of hyperphosphorylated tau staining.  
 
What might be the mechanism through which Cat316 affects memory? The action is 
probably through PNNs. PNN-mediated CS-GAGs make up only 2% of total brain CS-
GAG (Deepa, et al., 2006), and both ChABC and Cat316 will therefore bind to CS-
GAGs both on the PNNs and in the loose extracellular matrix, although injected Cat316 
bound preferentially to PNNs rather than to the surrounding diffuse matrix. PNNs can 
be attenuated through transgenic deletion of the Crtl1 link protein without affecting the 
overall quantity or sulphation pattern of CSPGs in the CNS (Carulli, et al., 2010). These 
animals with attenuated PNNs show exactly the same prolongation of OR memory that 
we obtained with Cat316 treatment (Romberg, et al., 2013). Cat316 bound to 
extracellular matrix, predominantly PNNs when injected into the brain, suggesting that 
Cat316 is acting on PNNs. Much of the work on CSPGs and plasticity and memory 
has depended on ChABC digestion of CSPG CS-GAGs. This has effects via PNNs, 
but it also enhances sprouting and synapse dynamics generally (Donato, et al., 
2013,Fawcett, 2015,Orlando, et al., 2012). In brains affected by tauopathy or other 
forms of neurodegeneration, where scattered neurons are non-functional, sprouting 
will enable some rewiring and formation of bypass circuits to restore function. It is 
possible, therefore, that both ChABC and Cat316 can restore function in 
neurodegeneration both through an effect on PNNs and through an effect on 
plasticity/sprouting. How might Cat316 affect PNN function? PNNs have a unique 
sulphation pattern which differs from that of the general CNS matrix, which allows them 
to have specific binding properties (Deepa, et al., 2006,Yabuno, et al., 2015). This 
enables PNNs to bind specifically to Sema3A and Otx2, which are therefore 
concentrated in PNNs where they can affect synapse dynamics and PV cell maturity 
(Bernard and Prochiantz, 2016,Beurdeley, et al., 2012,de Winter, et al., 2016,Dick, et 
al., 2013,Vo, et al., 2013). We have shown previously that Sema3A binds most strongly 
to C4,6S disulphated CS-E (Dick, et al., 2013), yet in the present paper we are 
demonstrating that an antibody to C4S monosulphated CS-A blocks binding. The 
probable explanation is that C4,6S CS-E makes up less than 2% of the total CS-GAG 
while C4S CS-A is over 90%. Specific binding sites on CS chains are usually 8 or more 
sugars in length, so it is probable that a Sema3A binding site will contain both C4S 
and C4,6S disaccharides, enabling Cat316 to interfere with binding. Blocking the 
Sema3A receptors neuropilin 1 and 2 can reactivate ocular dominance plasticity in the 
visual cortex (Pizzorusso, unpublished observations). It is probable, therefore, that the 
ability of Cat316 to reduce the binding of Sema3A to PNNs is a significant part of its 
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mechanism of action. Memory requires the formation of new inhibitory synapses on 
PV interneurons (Donato, et al., 2015), and it is probable that CS-GAGs, mostly being 
consisted of C4S might attenuate the formation of these new connections, while 
Cat316 will reduce this inhibition and enhance the formation of new synapses on PV 
interneurons.  
 
Our report shows that masking of the inhibitory 4-sulphated CS-GAGs on CSPGs 
using anti-CSPGs antibody can restore memory in a neurodegenerative condition. 
However, because Cat316 is an IgM we injected it directly into the brain. An antibody 
or blocking molecule with better ability to cross the blood-brain-barrier might be a 
useful treatment for memory loss when given systemically.  
As with any therapeutic antibody there is a possibility of immune damage with systemic 
administration. The tissue of obvious concern is cartilage; however most of the CS in 
cartilage is 6-sulphated and CS in joint cartilage is not exposed to blood and only 
indirectly to synovial fluid (Lauder, et al., 2001,Lauder, et al., 2000). CS autoantibodies 
are found in most normal adults and may be up-regulated in autoimmune conditions, 
but there is no direct evidence that the antibodies are the cause of damage (Gyorgy, 
et al., 2008). 
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Figure legends 
 
Fig. 1. Cat316 antibody bound to CS-A and aggrecan. Representative image of a slot 
blot demonstrating the binding specificity of Cat316. Cat316 antibody bound 
preferentially to CS-A (at both 2 and 10 µg/ml) and aggrecan (10 µg/ml). 
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Fig. 2. Cat316 antibody neutralised inhibition of DRG neurite outgrowth by aggrecan. 
Dissociated DRG neurons were cultured on laminin or laminin/aggrecan coated 
coverslips treated with PBS, ChABC or Cat316 antibody. The neurons were then 
stained with anti-betaIII tubulin antibody to reveal neurites. The length of the longest 
neurite per neuron was measured (20 neurons per coverslip, 3 coverslips per condition 
repeated 4 times). Data represents the mean r S.D., n=4, one-way ANOVA with post-
hoc analysis p **< 0.01 and p *** < 0.001. 
 
Fig. 3. Cat316 blocked the development of PNNs in the PNN-HEK cells. 
Representative images of PNN-HEK cells cultured in the presence of anti-HAPLN1 (C) 
Cat316 (D) and the anti-aggrecan antibodies 6B4 (E) and 7B7 (F). For controls cells 
were grown in the absence of antibodies, then treated before staining with PBS (A) or 
with ChABC (B). The cells were then labelled with aggrecan (red) for PNNs and 
counterstained with Hoechst (blue). For quantification the optical density of aggrecan 
staining on the cell surface was measured and normalised to the PBS control (n=4, 
two-tailed paired t- test, *** p < 0.001) (G). Cell surface CSPGs were also stained with 
WFA lectin which binds to CS-GAGs which are digested by ChABC (H). All the 
antibodies reduced PNN formation, with anti-HAPLN1 and Cat316 having the 
strongest effects. (n=4, two-tailed paired t-test, ***p <0.001). Bar= 50 um. 
 
Fig. 4. Cat316 binds to GAGs isolated from either diffuse ECM or PNNs. GAGs isolated 
from diffuse buffer-soluble ECM (B1) and the 6M urea soluble fraction enriched in PNN 
(B4) were biotinylated and immobilized on streptavidin-coated ELISA plates. Cat316 
demonstrated binding to both GAGs (bar 1 and 3). This binding was greatly reduced 
when the coated GAGs were treated with ChABC for 30 minutes before the Cat316. 
n=3, Student t-test, ***p <0.001. 
 
Fig. 5. Cat316 inhibits binding of Sema3A to PNN GAGs and to PNN-HEK cells. A) 
PNN-GAGs extracted from adult rat brain in buffer 4 of the progressive extraction 
method (Deepa, et al., 2006), were biotinylated and adhered to streptavidin-coated 
ELISA plates. Binding of alkaline phosphatase-tagged Sema3A was measured in the 
presence and absence of Cat316. n=4, *** p<0.001. B-D) Cat316 inhibits Sema3A 
binding to PNN-HEK cells. Sema3A-AP with or without Cat316 were added for 2 h to 
PNN-HEK cells, then immunostained. Optical density was measured and plotted in 
(D). n=4, ***p<0.001. 
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Fig. 6. Cat316 enhances DRG neurite growth on GAGs isolated from PNN-HEK and 
Sema3A. Dissociated DRG neurons were plated on coverslips first treated with 
laminin/PDL overnight, then coated with GAGs from PNN-HEK, followed by Sema3A-
AP (1:10) for 2 h. Cat316 or control IgM was then added for another 2 h. Adult 
dissociated DRG neurons were plated on the substrate, and neurite length measured 
24 h later. ,PPXQRVWDLQLQJRIȕ-tubulin (red) was performed and the longest neurite 
per neuron was measured. (A-B) Representative images of the DRG neurons cultured 
on the GAGs with or without the presence of Cat316. (C) A graph showing the length 
of neurites. Cat316 antibody increased the length of the DRG neurites. Results were 
analyzed using two-tailed student t-test. Data presents the mean ± SEM from three 
experiments (n=3 per condition), * p < 0.05. Scale bar, ȝP 
 
Fig. 7. Cat316-binding to brain tissue was prevented by ChABC treatment.  
The free-floating tissues of mouse brains (retrosplenial cortex) were pre-incubated with 
or without ChABC at different concentrations (0, 0.01, 0.1 and 1 U/ml).  They were 
stained with either Cat316 or biotin-WFA. (A) The immunostaining of Cat316 antibody 
without ChABC treatment showed typical structures of perineuronal nets around cell 
bodies and proximal dendrites as indicated by arrows. The PNNs labeling of Cat316 
was gradually reduced with increasing concentrations of ChABC pre-treatment. 
Immunohistochemistry without Cat316 incubation showed no staining. (B) WFA 
labelling of PNNs and ECM was absent after ChABC digestion. Scale bar, 50 ȝP  
 
Fig. 8. Injection of Cat316 into mouse brain. A. The antibody bound areas were 
detected in C57BL/6J WT mice at 5, 7 and 10 days post-injection with anti-mouse IgM 
at three different levels; bregma -1.8 mm, bregma -2.8 mm, bregma -3.8 mm. B. 
Cat316 binding on PNNs compared with isotype control IgM after injection to the 
cortex. Cat316 bound to PNNs at the edge of the injection site (a), and the centre of 
the injection area (c).  Equivalent control IgM injections are in (b) and (d), showing 
diffuse stain only. (e) At high magnification (40x) typical PNN profiles of Cat316-
labelled PNNs were seen. The binding pattern revealed the typical lattice-matrix 
around neuronal cell bodies and dendrites. Scale bar; 2mm (A); 30 µm (B) 
 
Fig. 9. Staining for Sema3A and WFA was altered after Cat316 treatment in vivo. A. 
Sema3A staining was measured 4 days post-injection in the Cat316 infused area, 
outlined in both sections.  Representative images were captured at two different sites 
as boxed in the Cat316 injected area; I and II. B. Images of the sites I and II in A were 
captXUHGDW[PDJQLILFDWLRQDQG,¶DQG,,¶DUHWKHFRXQWHUSDUWVLQ isotype control IgM 
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injections. The Cat316 injected area showed a reduced area of intense of Sema3A 
staining of PNNs compared to the sham injection. C. Quantification of the pixel number 
per frame of intense Sema3A staining from the thresholded pictures, normalised to the 
isotype control injection (33 % reduction, n=4, 0.67 ± 0.06, two-tailed paired t test, 
*p=0.0157). D. WFA staining was reduced in the Cat316 infused area compared to 
sham. E. Quantification of the number of thresholded pixels per frame of WFA staining 
was normalised to isotype control injection (27% reduction, n=4, 0.73 ± 0.073, two-
tailed paired t test, * p=0.0243). Scale bar; 1mm (A); 30 µm (B, D) 
 
Fig. 10. Cat316 treatment enhances long-term memory in WT control mice 
A. Experimental time line for the OR test after Cat316 or isotype control IgM injection. 
B. Three month-old C57BL/6J WT mice were injected with Cat316 antibody or isotype 
control IgM. At 4 - 5 days post-injection, their long-term object recognition memory was 
tested in the spontaneous OR paradigm with 24 h delay. Cat316 injected WT mice 
showed a large enhancement of OR memory compared to controls (Control n=9, 
Cat316 n=11, two-tailed unpaired t-test, ** p=0.0049). Their exploratory behavior in the 
sample phase did not differ, indicating that motivation was not altered by Cat316 
injection. C. Cat316 treated mice were tested in the OR task at day 8 and day 11 post-
injection to demonstrate the time scale of wash out of the effect (Day 8; Control 0.131 
± 0.08, n=8 vs Cat316 0.19 ± 0.07, n=10, Day 11; Control -0.006 ± 0.08, n=9 vs Cat316 
0.033 ± 0.08, n=11). Motivation was not affected by injection and there was no side 
preference. Data = mean ± SEM. ** p<0.01 
 
Fig. 11. Cat316 treatment restored the memory deficit in transgenic P301S mice A. 
The progression of the memory deficit in OR memory measured at 3 h was age-
dependent in P301S mice. No deficit was present in 3 month-old mice compared to 
C57BL/6J WT mice (WT 0.37 ± 0.12, n=4 vs P301S 0.36 ± 0.06, n=5), while 4 and 5 
month-old P301S mice showed a spontaneous OR memory deficit in the 3 h retention 
paradigm. The discrimination ratio is (novel - familiar object exploration time)/total 
exploration time). The OR memory deficit was significant in 4 and 5 month-old P301S 
mice compared to control mice (4M: WT 0.34 ± 0.05 n=8 vs P301S 0.07 ± 0.03, n=10, 
two-tailed unpaired t-test, *** p=0.0006, 5M: WT 0.32 ± 0.06 n=7 vs P301S 0.039 ± 
0.06, n=5, two-tailed unpaired t-test, ** p=0.0049). There was no exploration deficit in 
sample phase and no side bias. B. Experimental time line for the OR test after Cat316 
or isotype control IgM injection. C. Four month-old P301S mice were tested in the 
spontaneous OR task with 3 h delay following isotype control or Cat316 or ChABC 
treatment to the PRh cortex. The OR deficit exhibited in the P301S mice was restored 
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by Cat316 treatment to the level of normal WT control (WT: Isotype control 0.316 ± 
0.04 n=6, P301S: Isotype control 0.047 ± 0.09, n=8; Cat316 0.28 ± 0.04, n=14; ChABC 
0.24 ± 0.05, n=6, One way ANOVA, *p=0.042). Long-term memory was measured in 
24 h delay of OR paradigm after the same treatment in P301S mice. Data are 
presented as mean ± SEM. 
 
Fig. 12. Tauopathy after Cat316 treatment in Tg P301S mice. A. Hyperphosphorylated 
tau was visualized by AT8 antibody immunostaining in the PRh of isotype control IgM 
or Cat316 antibody injected mice at 7 days post-injection. B. Quantification of AT8-
positive tau tangles in the PRh cortex presented no difference (Istotype control vs 
Cat316, unpaired t-test, n.s. p=0.925) C. NeuN-positive cells were stereologically 
quantified in the PRh cortex of P301S mice. No significant influence of Cat316 
treatment on AT8 staining or neuronal cell number was present in the Tg P301S mice. 
Tg P301S: Isotype control n=6, Cat316 n=6, WT: Isotype control n=4 for NeuN staining 
(WT: Isotype control vs P301S: Isotype control, unpaired t-test, **p=0.0056, P301S: 
Isotype control vs P301S: Cat316 n.s. p=0.415). Scale bar; 100 µm 
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